Treatments for sustained response in Alzheimer's disease
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests whether a treatment (atomoxetine or metformin) can help people with Alzheimer's disease maintain an improved state for at least 18 months. It may help you or a loved one stabilize symptoms and slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 55 or older (no upper age limit)
- You have a diagnosis of Alzheimer's disease or mixed Alzheimer's and vascular dementia
- A blood test or brain scan shows signs of Alzheimer's inside your body
- Your memory and thinking are still fairly good (score of 17 or higher on a special test)
- You can safely have an MRI brain scan (no metal implants or severe anxiety in scanners)
- You have a caregiver or family member who can join study visits with you
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a sequence of treatments to see if they can help people with Alzheimer's disease or mild cognitive impairment. It aims to slow down memory decline and improve daily function.
This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.
This trial tests a special supplement combination designed to support brain energy use in people with Alzheimer's. It aims to see if the supplement can help slow cognitive decline.
This trial tests whether a gentle, non-invasive brain stimulation (transcranial alternating current) can improve memory and thinking in people with early Alzheimer's or mild memory problems. It involves regular sessions of stimulation and check-ups over several months.
This trial tests an investigational drug called Neuroaid II (MLC901) for people with mild to moderate Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This study tests an oral medicine called T3D-959 for people with mild to moderate Alzheimer's. It aims to see if the drug can help slow memory and thinking decline over time.
Hear when a new Alzheimer's Disease (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.